A selective method for distinguishing bacterial and nonbacterial adenosine triphosphate (ATP) in clinical bacteriological specimens was studied. The method involved incubation of samples with the detergent Triton X-100 and the ATP-hydrolyzing enzyme apyrase. The incubation selectively destroyed ATP in suspensions of various human cells while not affecting the ATP content in microbial cells. ATP remaining in the sample after incubation was extracted in boiling buffer and assayed by the firefly luciferase assay. Application of the method to 469 clinical urine specimens showed that the ATP level after treatment with Triton/apyrase was correlated to bacterial counts and that the sensitivity of the assay was sufficient for the detection of 105 bacteria/ml. The ATP levels per bacterial cell remaining in the urine specimens after treatment with Triton/apyrase were close to values observed in laboratory-grown cultures. The specificity and sensitivity of the luciferase assay for the detection of urinary bacteria and its possible use as a bacteriuria screening method are discussed.
Recently the assay of adenosine triphosphate (ATP) with the firefly luciferin/luciferase system has been discussed in connection with microbiological work. The most frequently proposed application has been the use of ATP assays as a means of quantitation of microbial cells in various samples (4, (10) (11) (12) (13) (14) 18 ; G. L. Picciolo and E. W. Chappelle, personal communication). Numerous studies have been made to determine cellular levels of ATP in both bacteria and other microorganisms (1, 3-5, 7, 9, 10, 12, 15) , demonstrating that variations in cellular ATP content rarely exceed one order of magnitude (1, 6, 10, 12) . Thus, it would seem that, theoretically, the accuracy of the assay is adequate for many microbiological applications.
The luciferase assay has been shown to have a sensitivity allowing the detection of approximately [10] [11] [12] [13] [14] M ATP, corresponding to the ATP content of fewer than 10 bacteria/ml (1, 10) . This extreme sensitivity, combined with the simple and rapid assay procedure, would make the luciferase assay an attractive alternative to existing methods for quantitation of bacteria.
A major problem in the application of ATP assays to quantitative bacteriology has been the frequent occurrence of large amounts of nonbacterial ATP emanating from cellular material present in many types of bacteriological specimens. If nonbacterial ATP cannot be removed prior to the assay, erroneous results will be obtained (13, 14) . The present study was performed to investigate the occurrence of nonbacterial ATP in urine and possible ways of its elimination. It has been suggested that the action of the detergent Triton X-100, selectively lyzing nonbacterial cells, combined with the ATP-hydrolyzing enzyme apyrase, might be used for this purpose (Picciolo and Chappelle, personal communication). The procedure was worked out in a model system including several types of human cells representative of cells likely to occur in urine specimens. The analytical system arrived at through these studies was applied on urine specimens sent for routine culture to a clinical bacteriological laboratory.
MATERIALS AND METHODS Analytical equipment. The analytical equipment used in the luciferase assay of ATP was a modification of a device originally described by Chappelle et al. (2) .
It consisted of a dark chamber into which the sample to be analyzed was introduced, so that it faced a photomultiplier, RCA 931 Quantitative culture. Quantitative culture was performed on all bacteriological specimens by plating on blood agar plates 0.2 ml of 10-fold serial dilutions in sterile saline. In Fig. 4 Pretreatment of urine specimens and bacterial cultures before assay. When nonbacterial ATP was to be removed, samples were incubated with apyrase in the presence of Triton X-100. The procedure finally adopted was as follows: 1 ml of the bacteriological specimen was made up to contain 0.1% Triton X-100, 2 mM CaSO4, and 0.1% apyrase (0.4 units) in a total volume of 2 ml. The mixture was then incubated for 10 min at 37 C, after which a 1-ml sample was pipetted into 4 ml of boiling 0.1 M tris(hydroxymethyl)aminomethane (Tris) buffer, pH 7.75, containing 2 mM EDTA to extract ATP. From non-pretreated samples, 0.5-ml portions were taken directly from the sample and extracted in 4.5 ml of boiling Tris buffer. After heating for 90 s, the extracts were cooled and kept on ice or frozen until the assay was performed. This extraction procedure gave reproducible results with all bacteria tested. The recovery of ATP was 76 to 99% compared with acid extraction procedures such as KCIO4 or trichloroacetic acid extractions. Nevertheless, the Tris-EDTA extraction was preferred because of its great technical advantages. Assay procedure. The assay was performed on 1-ml portions of the boiling buffer extracts which were transferred to 4-ml polystyrene Ellerman tubes and placed in the dark chamber of the luminometer. Luciferase reagent (0.4 ml) was then injected into the extract by means of a 1-ml syringe driven by a linear motor. Standards with known amounts of ATP and reagent blanks were assayed in each series.
Calculation of assay results. The ATP levels of the urine samples were calculated by using assays of standard amounts of ATP as reference and correcting for reagent background values. The ATP concentration arrived at in this way had to be further corrected for effects of interfering components present in the extracts. In the model experiments with pure bacterial cultures and human cells, a correction factor was obtained by the addition of a known amount of ATP to the extract followed by repeated assay.
In the clinical urine specimens, an average correction factor was determined to be 2.7
1.1 (95% confidence level), corresponding to an inhibition of the analytical reaction of about 60%, and all assay results were corrected by multiplication with this factor. Thus, the ATP concentrations determined for the urine specimens include a statistical error of ±40%
(95% confidence level).
RESULTS
In the first series of experiments, the Triton/ apyrase treatment was developed and applied to model systems of human and bacterial cells. In Fig. 1 , the time course of the effects of the treatment on ATP levels in human red blood cells and E. coli is shown. The treatment resulted in the complete elimination of ATP from the red blood cells within 2 min. The rate of ATP breakdown was identical to that ob- cells/ml, and E. coli (0), 109 cells/ml, were incubated in sterile urine (diluted 1:1 in distilled water) containing apyrase (0.2 unit/ml) and Triton X-100 (0.1%) at 37 C. At the times indicated, 1.0-ml portions were extracted and assayed. served with free ATP; i.e., the detergentinduced lysis of red blood cells was not rate limiting. The upper curve in Fig. 1 demonstrates the effect of the same treatment on E. coli. With the bacteria, essentially no effect on the ATP level was observed, except for a slight decrease at the start of the incubation, possibly resulting from metabolic disturbance caused by 'the transfer of the bacteria to the incubation medium. In the following experiments, an incubation time of 10 min was used.
In the experiment shown in Fig. 2 , four different types of human cells were treated at various concentrations of Triton X-100 in the presence of a constant amount of apyrase. For comparison, a strain of E. coli was included. At 0.1% Triton X-100, the loss of ATP was complete with all types of human cells, whereas E. coli was not affected even at higher concentrations. A concentration of 0.1% Triton X-100 was chosen for use in all of the following experiments.
In Table 2 , the effect of Triton/apyrase treatment on various cells of human and microbial origin is summarized. The treatment resulted in an almost complete loss of ATP in all human cells, whereas the microbial cells were more or less resistant to the treatment. In the absence of Triton X-100, no effect of the apyrase was observed on either type of cells. Thus, in all of the model experiments, the Triton/apyrase treatment resulted in the desired differential effect. Subsequent experiments were performed to evaluate the effect of Triton/apyrase treatment in a clinical material.
To determine whether nonbacterial ATP in In this experiment, the difference between posi-A tive and negative urine specimens is pronounced and most of the negative specimens fall below the detection limit of the assay, which was approximately 10-10 M ATP. Positive specimens are not affected or even show slightly increased ATP levels, as also shown in Fig. 3B and several of the model experiments. The In the present material, the ability of the assay to identify the cultivation-positive speci-;s. Both types of treatments re-mens is adequate up to an ATP concentration eased levels of ATP in all speci-limit of approximately 4 x 10-9 M, as shown in Zr, in most specimens the treat- Fig. 5 . When this ATP concentration is defined nsiderably more efficient when as the lower limit for a sample to be regarded as was included. Thus, it appears "luciferase positive," 96% of the culture-posispecimens a major part of the tive specimens are classified as "positive" by iTP may be cellular since deter-luciferase assay, whereas only 20% of the cultd for the breakdown of ATP by ture-negative specimens have ATP levels exceeding the value of 4 x 10-9 M. The percentage Fig. 3B , the effects of the same of borderline specimens classified as "luciferase culture-positive urine specimens positive" is always higher than that of the rent from the effects on negative culture-negative specimens. n the average, these specimens
In Table 3 , average and median ATP levels r than decrease their ATP content per cell remaining after treatment with Triton/ ie treatments, and there is also no apyrase are shown for different bacterial species ence between treatment with or in culture-positive urine specimens. As a com-X-100.
parison, results from laboratory experiments am of Fig. 4A presents the ATP with bacterial strains grown in sterile urine are Triton/apyrase treatment in a included. In spite of large variations in cellular the material studied, 319 speci-ATP content within each group of organisms, l. It is evident that there are there is a striking similarity between the aver-ATP content between negative age ATP levels per cell in the clinical specimens rine specimens. Median levels of and those obtained in the model studies. In the 5 x 10-8 and 1.4 x 10-7 M, case of Proteus, there is a tendency to low However, considerable overlap-values, and the lower ATP content of this ind the ATP assays under these organism was also observed in the model experinot give a reliable indication of ments. of bacteria.
In Fig. 6 , the ATP content of the 86 positive the same clinical material was urine specimens shown in Table 3 For practical purposes, however, the criterion for a "luciferase-positive" assay may be shifted towards somewhat higher levels of ATP, resulting in a lower number of "false positives," as shown in Fig. 5 . Thus, in any particular clinical material it may be worthwhile to establish empirically the concentration limit of ATP resulting in the highest degree of specificity.
"False-positive" results obtained with the luciferase assay might partly be caused by a failure to detect all bacteria by culture because of unusual nutrient or anaerobic requirements or because of the presence of antibiotics in the urine. In the borderline group, the reason for the relatively high numbers of "false positives' might, in addition, be a lack of precision in the reference method, making the correct classification of these specimens somewhat uncertain.
The present study has shown that luciferase assay of ATP may be a potentially useful method for bacteriuria screening. The sensitivity is sufficient to detect the presence of 105 bacteria per ml of urine, and the specificity allows the elimination of a majority of the culture-negative specimens, in a totally unselected clinical material. The Table 3. simplified by automation (17) . Further studies on the luciferase assay as a bacteriuria screening method are underway. They include the investigation of a larger clinical material and the development of equipment and assay procedures suited for routine work. An investigation is also being made to determine the cause of remaining discrepancies between ATP assays and culture. 
